HARMONY reaches milestone capturing data from 45,000 patients with blood cancers

MPE, MyelomaLeave a comment

  The HARMONY Alliance is a public-private partnership of more than 80 organizations (53 Partners and 35 Associated Members) funded by the Innovative Medicines Initiative for a period of 5 years (2017-2021). Myeloma Patients Europe (MPE) is part of the HARMONY Patient Cluster which is a unique group of 7 European Patient Umbrella Organizations working in the different areas of hematological diseases within the HARMONY Alliance.

Myeloma Patients Europe webinar on personalised medicines in myeloma

MPELeave a comment

  Myeloma is the disease with the highest number of approved drugs over the last 15 years. Actually, the prognosis of the disease has been tripled. As myeloma is a very heterogeneous disease, not all treatments are suitable for each patient. The challenge now is to choose the right treatment for each individual patient in order to improve patient health outcomes, increase the value of new medicines to healthcare systems and reduce healthcare costs. With…

Survey on myeloma patient information needs – UK patients required

MPE, Myeloma, Patient evidenceLeave a comment

  Myeloma Patients Europe (MPE) and Amgen are launching a survey for European myeloma patients to understand their information needs. If you are a myeloma patient living in the UK, who has received at least one prior treatment or are currently on your first treatment, MPE would be very grateful if you would take the time to complete the anonymous survey. The survey will be run in 12 European countries, however, at this stage we…

Call to action for Central and Eastern European (CEE) members – join MPE CEE workgroup on access

Access, MPELeave a comment

Myeloma Patients Europe (MPE) has launched a Central and Eastern Europe (CEE) Workgroup on Access during our recent Annual General Meeting (AGM) in Munich, Germany. The Workgroup is chaired by MPE board members, Kristina Modic, also CEO of our Slovenian member Slovensko Združenje Bolnikov Z Limfomom In Levkemijo L&L, and Biba Dodeva, President of our Macedonian member BORKA. It was launched in response to an identified need for coordinated action at a European level on…

Results of MPE members participation in EMA survey on bortezomib

MPE, Myeloma, Patient evidenceLeave a comment

As bortezomib, an anti-myeloma medicine, is licensed as both an intravenous (IV – through the vein via a drip) and subcutaneous medicine (through the skin, via an injection), the European Medicines Agency (EMA) recently conducted a survey to understand which method was most commonly used across Europe. They also asked about the location of administration (i.e. at home or in hospital) for patients.